Clinical trials: Stress Disorder, Post-Traumatic
Chronic Pain, Anxiety
Phase II Trial of Nu-V3 Non-Invasive Nerve Stimulation Device for Chronic Pain, Anxiety, Depression, Sleeplessness
This Nu-V3 clinical study is a randomized, phase II, open-label study evaluating the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.
- Conditions
- Chronic Pain, Anxiety, Depression, Sleeplessness
- Trial name
- Nu-V3P2RCT (NCT05394545)
- Testing
- Nu-V3
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nu-Life Solutions
Posttraumatic Stress Disorder
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The purpose of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with PTSD. The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?…
- Trial name
- NUMCAP1 (NCT04968938)
- Testing
- midomafetamine, Therapy
- Sponsor
- Resilient Pharmaceuticals
Post Traumatic Stress Disorder
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
- Trial name
- NCT05178316
- Testing
- JZP150
- Where
- 52 sites in United States
- Volunteers
- 282 people
- Sponsor
- Jazz Pharmaceuticals
Posttraumatic Stress Disorder (PTSD), Borderline Personality Disorder (BPD)
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and BPD
The goal of PROSPER-B is to study effectiveness of EMDR compared to integrated DBT-EMDR in treatment-seeking, adult patients with comorbid PTSD and Borderline Personality Disorder (BPD).
- Trial name
- PROSPER-B (NCT03833453)
- Testing
- EMDR, DBT
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Arkin
Post-Traumatic Stress Disorder
Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder
The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.
- Trial name
- NCT00306540
- Testing
- Quetiapine Fumarate
- Where
- 3 sites in Australia
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
PTSD
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT03282123
- Testing
- Midomafetamine, Manualized therapy
- Where
- 12 sites in United States
- Volunteers
- 38 people
- Sponsor
- Resilient Pharmaceuticals
Post-traumatic Stress Disorder
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
A growing body of evidence suggests that translingual neurostimulation (TLNS) plays a role in modulating neuroplastic changes in the brain, which has far-reaching implications for its ability to facilitate other therapeutic…
- Trial name
- NCT05112003
- Testing
- Translingual neurostimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- HealthTech Connex Inc.
Posttraumatic Stress Disorder
Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD.
- Trial name
- NCT01211405
- Testing
- Low dose MDMA-assisted therapy, Medium dose MDMA-assisted therapy, Full dose MDMA-assisted therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Post Traumatic Stress Disorder
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks.
- Trial name
- IMPACT-EXT (NCT06237426)
- Testing
- Methylone
- Where
- 9 sites in United States, Ireland and 1 more
- Volunteers
- 44 people
- Sponsor
- Transcend Therapeutics
PTSD, Generalized Anxiety Disorder
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms.
- Conditions
- PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT05717439
- Testing
- CAPS-5-R, Senseye DT
- Where
- 5 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
PTSD, Emotion Regulation Disorders
Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms
Around 10% of post-active veterans experience post-traumatic stress disorder (PTSD) many years post-mission. PTSD in veterans is frequently associated with challenges in emotion regulation, aggression, suicidality, and financial…
- Conditions
- PTSD, Emotion Regulation Disorders, Substance Abuse
- Trial name
- REFRESH (NCT07652645)
- Testing
- Hybrid dialectical behavior therapy
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Arkin
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.
- Trial name
- MAPPUSX (NCT04714359)
- Testing
- Midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Resilient Pharmaceuticals
PTSD, Sleep Disturbance
Electrical Vestibular Nerve Stimulation (VeNS) as a Method of Sleep Management in People With PTSD
This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation.
- Conditions
- PTSD, Sleep Disturbance, Insomnia
- Trial name
- NCT04780893
- Testing
- Modius Sleep
- Volunteers
- healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
PTSD, Anxiety
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy…
- Conditions
- PTSD, Anxiety, Anxiety Disorders, Depression
- Trial name
- EMPOWER (NCT04965740)
- Testing
- Cannabis
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Empower Research Inc
Chronic Insomnia, Sleep Deprivation
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders.
- Conditions
- Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder
- Trial name
- PSHW (NCT06644573)
- Testing
- PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nyree Penn
PTSD - Post Traumatic Stress Disorder, PTSD
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team.
- Conditions
- PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
- Trial name
- Redefine (NCT07570654)
- Testing
- COMP360 psilocybin
- Where
- 10 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- COMPASS Pathways
Stress Disorders, Post-Traumatic
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)
This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.
- Trial name
- NCT05401565
- Testing
- Balovaptan
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Post-Traumatic Stress Disorder in Adolescence
The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD.
- Trial name
- NCT06854328
- Testing
- Prism
- Where
- 2 sites in United States, Israel
- Volunteers
- 45 people
- Sponsor
- GrayMatters Health Ltd.
PTSD
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label…
- Trial name
- P306 (NCT03508700)
- Testing
- TNX-102 SL 5.6 mg
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Tonix Pharmaceuticals, Inc.